ArticleFrontiers in public health2023
Recommendations for patient involvement in health technology assessment in Central and Eastern European countries.
Article in Frontiers in public health, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- Fetal Magnetocardiography Using Optically Pumped Magnetometers: A Literature Review.Biosensors · 2026Review
- Rethinking Slovenia's HTA System.International journal of technology assessment in health care · 2026Article
- Exploring the challenges of developing hospital-based health technology assessment in Iran: a qualitative study.Health research policy and systems · 2026Article
- Assessing the Early Economic Feasibility of a Curative Gene Therapy for Multiple Sclerosis Using a Risk-Adjusted Valuation Framework.Healthcare (Basel, Switzerland) · 2026Article
- Optimizing OPM-MEG Sensor Layouts Using the Sequential Selection Algorithm with Simulated Sources and Individual Anatomy.Sensors (Basel, Switzerland) · 2026Article
- The Significance of Hypophosphatemia in Deciding on an Optimal Clinical Choice of Parenteral Iron Therapy in Patients with Chronic Inflammatory Bowel Disease in Slovenia: An Umbrella Review and Economic Evaluation.Healthcare (Basel, Switzerland) · 2026Article
- International practices, barriers, and enablers for patient and public involvement in pricing and reimbursement decision-making: a mixed-methods study.Frontiers in pharmacology · 2026Article
- Comparison of somatic development, nutritional status, control of disease, and frequency of autoimmune comorbidities in Polish and Ukrainian children with type 1 diabetes.Pediatric endocrinology, diabetes, and metabolism · 2026Article
- Joint Clinical Assessments in Europe: Implications for Market Access, Reimbursement, and National HTA Alignment.Pharmaceutical medicine · 2026Review
- Validation of a method for synthesizing public consultations to inform decision-making in health technology assessment (HTA) in Brazil: a Delphi consensus.BMC health services research · 2025Article
- How Patients Can Contribute to the Assessments of Health Technologies.Journal of market access & health policy · 2025Article
- Plain language summaries supporting patient involvement: lessons and guidance from HTAi Patient and Citizen Involvement Interest Group (PCIG).International journal of technology assessment in health care · 2025Article
- Patient Engagement and Patient Experience Data in Regulatory Review and Health Technology Assessment: Where Are We Today?Therapeutic innovation & regulatory science · 2025Review
- Optimizing Patient Access to Orphan Medicinal Products: Lessons from Central and Eastern Europe.Journal of market access & health policy · 2025Article
- Navigating barriers to health technology assessment development in Iran: a qualitative exploration of stakeholder perspectives.Archives of public health = Archives belges de sante publique · 2025Article
- Preferences for public health insurance coverage of new anticancer drugs: a discrete choice experiment among non-small cell lung cancer patients in China.BMC public health · 2025Article
- Involving Patients in Hospital-Based Health Technology Assessment of Innovative Medical Devices: Adapting to a Specific Local Context and Lessons Learned From the Assessment of an Ex Vivo Perfusion System of Human Donor Hearts.Health expectations : an international journal of public participation in health care and health policy · 2024Article
- Availability and Access to Orphan Drugs for Rare Cancers in Bulgaria: Analysis of Delays and Public Expenditures.Cancers · 2024Article
- From Innovator Result-driven to Multi-actor Impact-oriented Public-Private Partnerships: Integrating the Patient Perspective.Handbook of experimental pharmacology · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
28 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Meaningful patient involvement in health technology assessment (HTA) is essential in ensuring that the interests of the affected patient population, their families, and the general public are accurately reflected in coverage and reimbursement decisions. Central and Eastern European (CEE) countries are generally at less advanced stages of implementing HTA, which is particularly true for patient involvement activities. As part of the Horizon2020 HTx project, this research aimed to form recommendations for critical barriers to patient involvement in HTA in CEE countries. Methods: Built on previous research findings on potential barriers, a prioritisation survey was conducted online with CEE stakeholders. Recommendations for prioritised barriers were formed through a face-to-face workshop by CEE stakeholders and HTx experts. Results: A total of 105 stakeholders from 13 CEE countries completed the prioritisation survey and identified 12 of the 22 potential barriers as highly important. The workshop had 36 participants representing 9 CEE countries, and 5 Western European countries coming together to discuss solutions in order to form recommendations based on best practices, real-life experience, and transferability aspects. Stakeholder groups involved in both phases included HTA organisation representatives, payers, patients, caregivers, patient organisation representatives, patient experts, health care providers, academic and non-academic researchers, health care consultants and health technology manufacturers/providers. As a result, 12 recommendations were formed specified to the CEE region's context, but potentially useful for a broader geographic audience. Conclusion: In this paper, we present 12 recommendations for meaningful, systematic, and sustainable patient involvement in HTA in CEE countries. Our hope is that engaging more than a hundred CEE stakeholders in the study helped to spread awareness of the importance and potential of patient involvement and that the resulting recommendations provide tangible steps for the way forward. Future studies shall focus on country-specific case studies of the implemented recommendations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.